The FDA's Drugs@FDA database lists a supplement to the biologics licence for teprotumumab-trbw, the IGF-1 receptor antibody used for thyroid eye disease, dated 23 September. The record names the application and the licence holder but does not state what the supplement covers.
Supplements range from manufacturing and labelling changes to new safety wording or an extended indication, and the database entry alone does not say which this is. Until the label itself is updated, treat this as administrative.
Teprotumumab already carries warnings on hearing impairment and on hyperglycaemia, including worsening control in people with pre-existing diabetes. For endocrinologists sharing care with ophthalmology, the practical checks are unchanged: baseline hearing questions or audiometry, and glucose monitoring during the course. Its availability and regulatory status in India are not established here.
- The 23 September entry is a licence supplement; the database does not say what changed.
- Hyperglycaemia is a labelled risk: check glucose and adjust therapy in people with diabetes during infusions.
- Ask about hearing before and during treatment, as hearing impairment is a labelled warning.
- Check the updated FDA label before assuming any change in indication or dosing.
Why it matters
Endocrinologists co-managing thyroid eye disease need to know when a label change touches glycaemic monitoring.
Don't overread it
A licence supplement is not a new indication or a new safety finding until the label says so.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for diabetes & endocrinology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free